Yiran Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/880366/publications.pdf

Version: 2024-02-01

100 papers 2,264 citations

236833 25 h-index 289141 40 g-index

106 all docs

106
docs citations

106 times ranked 3793 citing authors

#	Article	IF	Citations
1	Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study. Future Oncology, 2022, 18, 1461-1471.	1.1	2
2	Longitudinal personalized urinary tumor DNA analysis in muscle-invasive bladder cancer from the neoadjuvant immunotherapy trial RJBLC-I2N003 Journal of Clinical Oncology, 2022, 40, 552-552.	0.8	1
3	Prospective Clinical Trial of the Oncologic Outcomes and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma. Frontiers in Oncology, 2022, 12, 791140.	1.3	2
4	Cognitive Function after Cardiopulmonary Bypass and Deep Hypothermic Circulatory Arrest in Management of Renal Cell Carcinoma with Vena Caval Thrombus. Urology, 2022, , .	0.5	0
5	SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis. Acta Pharmaceutica Sinica B, 2021, 11, 406-419.	5.7	56
6	PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics, 2021, 11, 5387-5403.	4.6	36
7	DNA damage repair (DDR) pathway alteration in advanced renal cell carcinoma (RCC) is association with good progression-free survival with tyrosine kinase inhibitor (TKI) therapy Journal of Clinical Oncology, 2021, 39, 346-346.	0.8	0
8	Hypoxia-induced IncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway. Molecular Therapy, 2021, 29, 2979-2994.	3.7	48
9	Dual Targeting of Endoplasmic Reticulum by Redox-Deubiquitination Regulation for Cancer Therapy. International Journal of Nanomedicine, 2021, Volume 16, 5193-5209.	3.3	12
10	Clinical outcomes of secondâ€line treatment following firstâ€line VEGFRâ€TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus antiâ€PDâ€1 antibody. Cancer Communications, 2021, 41, 1071-1074.	3.7	4
11	Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2021, 11, 697219.	1.3	5
12	Influence of American Society of Anesthesiologists Score on Oncologic Outcomes in Patients With Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Large-Sample Study in Two Institutions. Frontiers in Oncology, 2021, 11, 723669.	1.3	2
13	Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy. Journal of Cellular Physiology, 2020, 235, 2129-2138.	2.0	27
14	Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor. International Journal of Clinical Oncology, 2020, 25, 338-346.	1.0	3
15	PRKAR2Bâ€HIFâ€1α loop promotes aerobic glycolysis and tumour growth in prostate cancer. Cell Proliferation, 2020, 53, e12918.	2.4	36
16	Decreased ANGPTL4 impairs endometrial angiogenesis during periâ€implantation period in patients with recurrent implantation failure. Journal of Cellular and Molecular Medicine, 2020, 24, 10730-10743.	1.6	16
17	circPTCH1 promotes invasion and metastasis in renal cell carcinoma via regulating miR-485-5p/MMP14 axis. Theranostics, 2020, 10, 10791-10807.	4.6	55
18	miR-30a-3p inhibits renal cancer cell invasion and metastasis through targeting ATG12. Translational Andrology and Urology, 2020, 9, 646-653.	0.6	14

#	Article	IF	CITATIONS
19	Zero ischemia laparoscopic microwave ablation assisted enucleation vs. laparoscopic partial nephrectomy in clinical T1a renal tumor: a randomized clinical trial. Translational Cancer Research, 2020, 9, 194-202.	0.4	6
20	Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC Cancer, 2020, 20, 219.	1.1	12
21	Tumor-educated B cells promote renal cancer metastasis via inducing the IL-1β/HIF-2α/Notch1 signals. Cell Death and Disease, 2020, 11, 163.	2.7	20
22	Programming bulk enzyme heterojunctions for biosensor development with tetrahedral DNA framework. Nature Communications, 2020, $11,838$.	5.8	84
23	Transcriptional regulation of PRKAR2B by miR-200b-3p/200c-3p and XBP1 in human prostate cancer. Biomedicine and Pharmacotherapy, 2020, 124, 109863.	2.5	26
24	Co-Expression of Stem Cell and Epithelial Mesenchymal Transition Markers in Circulating Tumor Cells of Bladder Cancer Patients. OncoTargets and Therapy, 2020, Volume 13, 10739-10748.	1.0	13
25	Downregulation of circ-TRPS1 suppressed prostatic cancer prognoses by regulating miR-124-3p/EZH2 axis-mediated stemness. American Journal of Cancer Research, 2020, 10, 4372-4385.	1.4	7
26	Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. Cancer Communications, 2019, 39, 1-4.	3.7	14
27	CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition. Cell Communication and Signaling, 2019, 17, 118.	2.7	64
28	The m6A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca2+ influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 233.	3.5	82
29	A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma. Molecular Cancer, 2019, 18, 81.	7.9	71
30	ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma. Molecular Therapy - Nucleic Acids, 2019, 14, 550-561.	2.3	12
31	Dysregulation of collagen expression in periâ€implantation endometrium of women with high ovarian response. Journal of Obstetrics and Gynaecology Research, 2019, 45, 1035-1044.	0.6	7
32	Comparison Between 1-Day and Inpatient Procedure of Holmium Laser Enucleation in Patients With Benign Prostate Hyperplasia. American Journal of Men's Health, 2019, 13, 155798831989448.	0.7	4
33	LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling. Acta Pharmaceutica Sinica B, 2019, 9, 324-334.	5.7	44
34	Re: Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. European Urology, 2018, 74, 398-399.	0.9	2
35	Postoperative D-dimer predicts venous thromboembolism in patients undergoing urologic tumor surgery. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 307.e15-307.e21.	0.8	25
36	Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression. Journal of Cancer Research and Clinical Oncology, 2018, 144, 39-52.	1.2	22

#	Article	IF	CITATIONS
37	Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma. Oncogenesis, 2018, 7, 83.	2.1	10
38	Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. BMC Urology, 2018, 18, 110.	0.6	7
39	Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma. Oncolmmunology, 2018, 7, e1502130.	2.1	18
40	Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus. Urologia Internationalis, 2018, 101, 391-399.	0.6	10
41	PRKAR2B promotes prostate cancer metastasis by activating Wnt∫î²â€catenin and inducing epithelialâ€mesenchymal transition. Journal of Cellular Biochemistry, 2018, 119, 7319-7327.	1.2	31
42	MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis. British Journal of Cancer, 2018, 119, 591-604.	2.9	63
43	Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Human Pathology, 2018, 79, 151-159.	1.1	49
44	Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. International Journal of Oncology, 2018, 53, 515-526.	1.4	34
45	miRNA-335-5p negatively regulates granulosa cell proliferation via SGK3 in PCOS. Reproduction, 2018, 156, 439-449.	1.1	27
46	Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy. Clinical Genitourinary Cancer, 2017, 15, e437-e446.	0.9	27
47	A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naÃve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian Journal of Urology, 2017, 4, 75-85.	0.5	23
48	Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells. Cell Cycle, 2017, 16, 999-1007.	1.3	51
49	Comparing renal function preservation after laparoscopic radio frequency ablation assisted tumor enucleation and laparoscopic partial nephrectomy for clinical T1a renal tumor: using a 3D parenchyma measurement system. Journal of Cancer Research and Clinical Oncology, 2017, 143, 905-912.	1.2	7
50	Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy. International Urology and Nephrology, 2017, 49, 1955-1963.	0.6	20
51	Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 671.e1-671.e9.	0.8	26
52	Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Chinese Journal of Cancer, 2017, 36, 47.	4.9	8
53	Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. Journal of Urology, 2017, 197, 90-96.	0.2	44
54	The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2017, 8, 20825-20833.	0.8	15

#	Article	IF	Citations
55	Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma. Chinese Journal of Cancer, 2017, 36, 64.	4.9	18
56	Association of MAMLD1 single-nucleotide polymorphisms nbsp with hypospadias in Chinese Han population. Frontiers in Bioscience - Landmark, 2017, 22, 1173-1176.	3.0	8
57	Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma. Oncotarget, 2017, 8, 36761-36771.	0.8	26
58	Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Oncotarget, 2017, 8, 36772-36779.	0.8	31
59	PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer. Oncotarget, 2017, 8, 6114-6129.	0.8	21
60	Depletion of astrocyte elevated gene-1 suppresses tumorigenesis through inhibition of Akt activity in bladder cancer cells. American Journal of Translational Research (discontinued), 2017, 9, 5422-5431.	0.0	3
61	TIKI2 is upregulated and plays an oncogenic role in renal cell carcinoma. Oncotarget, 2016, 7, 17212-17219.	0.8	1
62	High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0166231.	1.1	31
63	Spherical cap surface model: A novel method for predicting renal function after partial nephrectomy. International Journal of Urology, 2016, 23, 667-672.	0.5	4
64	Abiraterone acetate for metastatic castrationâ€resistant prostate cancer after docetaxel failure: A randomized, doubleâ€blind, placeboâ€controlled phase 3 bridging study. International Journal of Urology, 2016, 23, 404-411.	0.5	26
65	c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma. International Journal of Oncology, 2016, 49, 1569-1575.	1.4	18
66	Transitional cell carcinoma with extension of the renal vein and IVC tumor thrombus: report of three cases and literature review. World Journal of Surgical Oncology, 2016, 14, 309.	0.8	9
67	Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer, 2016, 16, 329.	1.1	26
68	The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Scientific Reports, 2016, 6, 20089.	1.6	22
69	Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression. Tumor Biology, 2016, 37, 16237-16247.	0.8	9
70	Comparing Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Tumor Enucleation and Laparoscopic Partial Nephrectomy for Clinical T1a Renal Tumor: A Randomized Clinical Trial. Journal of Urology, 2016, 195, 1677-1683.	0.2	30
71	The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma. Tumor Biology, 2016, 37, 479-489.	0.8	12
72	Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps. Oncotarget, 2016, 7, 59189-59198.	0.8	58

#	Article	IF	CITATIONS
73	Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy. Oncotarget, 2016, 7, 63294-63305.	0.8	16
74	SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. Oncotarget, 2016, 7, 80435-80449.	0.8	24
75	Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget, 2016, 7, 3233-3244.	0.8	17
76	Chinese guidelines on the management of renal cell carcinoma (2015 edition). Chinese Clinical Oncology, 2016, 5, 12.	0.4	8
77	Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. OncoTargets and Therapy, 2015, 8, 1363.	1.0	14
78	Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. BioMed Research International, 2015, 2015, 1-9.	0.9	24
79	Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0Âng/mL: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Urology, 2015, 2, 107-113.	0.5	6
80	Endothelial Nitric Oxide Synthase (eNOS) T-786C, 4a4b, and G894T Polymorphisms and Male Infertility: Study for Idiopathic Asthenozoospermia and Meta-Analysis1. Biology of Reproduction, 2015, 92, 38.	1.2	16
81	Preoperative Anemia as an Independent Prognostic Indicator of Papillary Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e353-e360.	0.9	9
82	Molecular Mechanism underlying PRMT1 Dimerization for SAM Binding and Methylase Activity. Journal of Chemical Information and Modeling, 2015, 55, 2623-2632.	2.5	30
83	Catalpol Inhibited the Proliferation of T24 Human Bladder Cancer Cells by Inducing Apoptosis Through the Blockade of Akt-Mediated Anti-apoptotic Signaling. Cell Biochemistry and Biophysics, 2015, 71, 1349-1356.	0.9	29
84	Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml. PLoS ONE, 2015, 10, e0130308.	1.1	14
85	View changes and educational demands on sexual/reproductive health of students at Shanghai Jiaotong University. International Journal of Clinical and Experimental Medicine, 2015, 8, 16414-23.	1.3	3
86	SERS measurement of the bladder cancer cells with the nanoparticles. Pakistan Journal of Pharmaceutical Sciences, 2015, 28, 1853-6.	0.2	1
87	Incidental Prostate Cancer at the Time of Cystectomy: The Incidence and Clinicopathological Features in Chinese Patients. PLoS ONE, 2014, 9, e94490.	1.1	20
88	Mesenchymal stem cells overexpressing Ihh promote bone repair. Journal of Orthopaedic Surgery and Research, 2014, 9, 102.	0.9	19
89	Prostate cancer in Asia: A collaborative report. Asian Journal of Urology, 2014, 1, 15-29.	0.5	136
90	Raman spectroscopy as an exÂvivo noninvasive approach to distinguish complete and incomplete spermatogenesis within human seminiferous tubules. Fertility and Sterility, 2014, 102, 54-60.e2.	0.5	22

#	Article	IF	CITATIONS
91	miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumor Biology, 2014, 35, 5833-5843.	0.8	40
92	Knockdown of ubiquitin associated protein 2-like inhibits the growth and migration of prostate cancer cells. Oncology Reports, 2014, 32, 1578-1584.	1.2	28
93	Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms. Chinese Medical Journal, 2014, 127, 261-5.	0.9	2
94	Effect of remote ischaemic preconditioning on renal protection in patients undergoing laparoscopic partial nephrectomy: a †blinded†randomised controlled trial. BJU International, 2013, 112, 74-80.	1.3	45
95	Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment. Medical Oncology, 2013, 30, 436.	1.2	4
96	Hypoxiaâ€induced downregulation of mi <scp>R</scp> â€30c promotes epithelialâ€mesenchymal transition in human renal cell carcinoma. Cancer Science, 2013, 104, 1609-1617.	1.7	69
97	Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ) Journal of Clinical Oncology, 2013, 31, 366-366.	0.8	7
98	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study Journal of Clinical Oncology, 2012, 30, 4628-4628.	0.8	2
99	Axitinib versus sorafenib as secondâ€ʻline therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study Journal of Clinical Oncology, 2012, 30, LBA4537-LBA4537.	0.8	1
100	Axitinib versus sorafenib as secondâ€ʻline therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study Journal of Clinical Oncology, 2012, 30, LBA4537-LBA4537.	0.8	0